


PHARMACEUTICAL 2019

Dova Pharmaceuticals Inc. Rank 248 of 371





PHARMACEUTICAL 2019

Dova Pharmaceuticals Inc. Rank 248 of 371

The relative strengths and weaknesses of Dova Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dova Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Dova Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 203% points.

The company's Economic Capital Ratio, given in the ranking table, is -283%, being 48% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	111,807
Cost of Goods Sold	1,180
Intangible Assets	0
Liabilities, Current	19,497
Liabilities, Non-Current	2,373
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	13,941
Other Net Income	-1,232
Property and Equipment	362
Research and Development	18,304
Revenues	10,355
Selling, General and Administrative Expense	61,921

Output Variable	Value in 1000 USD
Assets	112,169
Liabilities	35,811
Expenses	81,405
Stockholders Equity	76,358
Net Income	-72,282
Comprehensive Net Income	-72,282
Economic Capital Ratio	-283%